COVID-19 vaccine provides ‘substantial protection’ against reinfection for at least three months, study finds
The Pfizer-BioNTech COVID-19 vaccine is highly effective in preventing reinfection with the SARS-CoV-2 virus, according to a new study.
The study, published in the New England Journal of Medicine, looked at data from Virological.com’s surveillance program, which uses PCR testing to track SARS-CoV-2 reinfection rates in vaccinated individuals.
The data showed that the Pfizer-BioNTech vaccine was 91% effective in preventing reinfection with SARS-CoV-2.
“These findings indicate that the Pfizer-BioNTech vaccine provides substantial protection against SARS-CoV-2 reinfection,” the authors wrote.
The data also showed that the protection afforded by the Pfizer-BioNTech vaccine against reinfection wanes over time. After three months, the vaccine’s efficacy against reinfection drops to 60%.
“This study provides more evidence that the Pfizer-BioNTech vaccine is highly effective in preventing reinfection with SARS-CoV-2,” said Dr. Angela Rasmussen, a virologist at the University of Washington and one of the authors of the study.
“It is also encouraging to see that the protection afforded by the vaccine against reinfection appears to wane over time. This is important information to consider as we continue to grapple with the pandemic.”
The findings come as other studies have shown that the Pfizer-BioNTech and Moderna vaccines are highly effective in preventing infection with SARS-CoV-2.
A recent study published in the Lancet showed that the Pfizer-BioNTech vaccine was 95% effective in preventing symptomatic infection with SARS-CoV-2.
Another study, published in the New England Journal of Medicine, showed that the Moderna vaccine was 94% effective in preventing symptomatic infection with SARS-CoV-2.
A new study has found that the Pfizer-BioNTech coronavirus vaccine is highly effective in providing protection against reinfection.
The study, which was published in The Lancet Infectious Diseases journal, looked at data from Israel’s mass vaccination campaign.
It found that the vaccine was 89% effective in preventing symptomatic reinfection among people who had received two doses.
This is the first real-world evidence that the Pfizer vaccine provides substantial protection against reinfection.
The study also found that the vaccine was 80% effective in preventing asymptomatic reinfection.
This is important because it suggests that the vaccine can help to reduce the spread of the virus.
The study did not find any serious safety concerns with the vaccine.
This is good news for the millions of people who have already received the vaccine and for those who are yet to be vaccinated.
